NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis

Enanta Pharmaceuticals, Inc. (ENTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ENTA

$14.08

+$0.06 (+0.43%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENTA with… →

ENTA Key Statistics

As of Sep 4, 2026
Trading
Open
$13.92
Previous Close
$14.02
Day's Range
13.45–14.23
52-Week Range
7.05–17.15
Volume
233.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.94
Valuation
Market Cap
$410.09M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.43
Financials (FY)
Revenue (FY)
$65.32M−3.42%
Net Income (FY)
−$81.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
−96.89%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.13M
1-Year Return
+58.38%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
215.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ENTA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−10.72%
2025+174.26%
2024−38.89%
2023−79.77%
2022−37.79%
2021+77.62%
2020−31.85%
2019−12.78%
2018+20.71%
2017+75.16%
2016 (partial year)+54.31%

As of September 4, 2026.

ENTA Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$65.32M−$81.89M−125.4%
2024$67.64M−$116.05M−171.6%
2023$79.20M−$133.82M−169.0%
2022$86.16M−$121.76M−141.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$65.32M—−$85.35M−$81.89M−125.4%
2024$67.64M—−$121.69M−$116.05M−171.6%
2023$79.20M—−$137.21M−$133.82M−169.0%
2022$86.16M—−$123.84M−$121.76M−141.3%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

ENTA Valuation vs Biotechnology Median

Median of 656 stocks
MetricENTABiotechnology medianvs median
P/S ratio6.2815.2659% below
Profit margin−96.89%0.00%96.9 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Enanta Pharmaceuticals, Inc. (ENTA) at $410.09M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 120.

The most recent close on file for ENTA is $14.08, dated September 4, 2026. That is +$0.06 (+0.43%) against the previous close. The 52-week range on file runs from $7.05 to $17.15. The latest close sits 99.72% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $65.32M. Against the prior fiscal year total of $67.64M, that is a change of −3.42%. The same year closed with a net loss of $81.89M. The reported profit margin is −96.89%. That is 96.9 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −2.43.

Across the 4 fiscal years on file, revenue moves from $86.16M in 2022 to $65.32M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 6.28. On price-to-sales that is 58.83% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +58.38%. Measured over 10 years, that is −4.38% a year compounded. Beta against the wider market is reported at 0.94. Annualized volatility over the trailing 10 years is 60.78%.

Growth & Income

No dividend is on file for ENTA.

Across the complete calendar years on file, 2025 returned +174.26% and 2023 returned −79.77%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −10.72% year to date.

Peer Comparison

Enanta Pharmaceuticals, Inc. (ENTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Enanta Pharmaceuticals, Inc. ENTA $410.09M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Enanta Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Visit website →